A phase 1 study (NCT02236013) of gilteritinib plus 7+3 AraC/IDR induction and high-dose AraC consolidation therapy in newly diagnosed AML patients [35], and a phase 2/3 study (NCT02752035) of gilteritinib plus Aza in newly diagnosed FLT3 mutation-positive AML patients have been initiated [36]. The gene discussed is FLT3; the disease is acute myeloid leukemia.